Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. (RVMD) reported that Chief Development Officer Alan B. Sandler sold a total of 341 shares of common stock on September 16, 2026, in open-market or private transactions at prices around $195–$199 per share.
The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy Mr. Sandler’s tax withholding obligation upon the vesting of restricted stock units. The reported holdings referenced in the footnotes include 209 shares acquired under the Employee Stock Purchase Plan and 52,350 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported that Chief Global Commercialization Officer Anthony Mancini sold a total of 1,774 shares of common stock on September 16, 2026 in open-market transactions under a Rule 10b5-1 trading arrangement adopted on June 15, 2026 to satisfy tax withholding on vesting restricted stock units.
The sales were executed at weighted average prices of $195.05 and $199.30 per share across narrow price ranges, and Mancini continues to hold equity awards, including 39,575 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported that senior advisor to the CEO Stephen Michael Kelsey sold a total of 5,569 shares of common stock on September 16, 2026, in open-market transactions made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units. One sale of 85 shares reflected a weighted average price between $195.00 and $195.03 per share, and the other sale of 5,484 shares was at $199.30 per share; reported holdings include 65,613 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported that Chief Operating Officer Margaret A. Horn sold a total of 4,967 shares of common stock on September 16, 2026 in open‑market transactions. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy her tax withholding obligation upon the vesting of restricted stock units.
The transactions included 76 shares at a weighted average price of $195.01 (with individual trades ranging from $195.00 to $195.03) and 4,891 shares at $199.30 per share. A related holding reported in the filing includes 56,713 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported that President and Chief Executive Officer Mark A. Goldsmith, who is also a director, sold 13,988 shares of common stock on September 16, 2026 in open-market transactions. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon the vesting of restricted stock units.
The transactions occurred at weighted-average prices of $195.01 and $199.30 per share across multiple trades. Goldsmith also has indirect holdings in family trusts, including the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and revocable trusts for Jonathan and Rebecca Goldsmith.
Revolution Medicines, Inc. (RVMD) disclosed that SVP & General Counsel Jeff Cislini sold a total of 3,366 shares of common stock on September 16, 2026 in open-market transactions, consisting of 52 shares at a weighted average price of $195.01 and 3,314 shares at a weighted average price of $199.30. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon the vesting of restricted stock units, and following these transactions his holdings include 37,088 restricted stock units. Each trade was executed in multiple lots within the disclosed price ranges.
Revolution Medicines, Inc. (RVMD) reported that its Chief Financial Officer, Anders Jack, sold a total of 4,053 shares of common stock on September 16, 2026, in two open-market transactions at prices around $195–$199.30 per share. According to the company’s disclosure, these sales were executed under a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units. Following the transactions, the CFO’s holdings include 43,650 restricted stock units.
Revolution Medicines, Inc. (RVMD) insider Anthony Mancini filed a notice to sell 1,764 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an estimated aggregate market value of $347,402.16. The filing also lists prior Rule 144 sales during the past three months.
Revolution Medicines, Inc. (RVMD) has a notice of proposed sale filed under Rule 144 for common stock held for the account of officer Alan B. Sandler. The filing covers up to 331 shares of common stock, to be sold through E*TRADE Financial Corporation after RSU vesting on September 15, 2026, as compensation for services rendered.
Revolution Medicines, Inc. (RVMD) was named as the issuer in a notice that officer Anthony Mancini intends to sell common stock under Rule 144. The notice covers a planned sale of 2,377 shares of common stock, with an aggregate market value of $484,361.29, with an approximate sale date of September 15, 2026.
The securities are to be sold through E*TRADE Financial Corporation, and the filing notes that 214,336,418 shares of RVMD common stock were outstanding. The shares to be sold relate to RSU vesting and are stated as being for services rendered. The form also lists prior common stock sales by Mancini during the previous three months.